AstraZeneca (AZN) Receives a Buy from Bernstein
Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £190.00. The ...
Fierce Pharma59m
AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer drugs despite Merck-Halozyme patent drama
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
Fierce Biotech4h
AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Eventful Monday For AstraZeneca - What's Going On?
AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...
AstraZeneca announces Imfinzi approved in European Union
Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...
Medical Dialogues5h
AstraZeneca to acquire EsoBiotec for up to USD 1 billion
Cambridge: AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in ...
FTSE 100 Live 17 March: AstraZeneca unveils £1bn deal, Qinetiq cuts guidance
Phoenix shares surge on upgraded guidance 08:26 , Graeme Evans The FTSE 100-listed shares of ...
Fierce Pharma3d
AstraZeneca embraces pickleball trend with Fasenra tour sponsorship, themed DTC ad
AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...